Payment overview · 2025
General Payments
$400.42
19 reported records · 6 companies
Healthcare provider profile · identity verified
Joshua Frederick, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BELOIT, WI · NPI 1952750549
Verified facts
What the public records show
CMS Open Payments records show Joshua Frederick, MD received $400.42 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 49.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.15 | 49.2% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.31 | 21.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.62 | 10.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.09 | 8.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.18 | 5.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.07 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $400.42 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.98 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.70 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.74 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 129 |
| Lisinopril | Lisinopril | 217 | 67 |
| Omeprazole | Omeprazole | 191 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 39 |
| Furosemide | Furosemide | 150 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 39 |
| Losartan Potassium | Losartan Potassium | 132 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 43 |
| Gabapentin | Gabapentin | 124 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 33 |
| Metformin Hcl | Metformin Hcl | 119 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 29 |
| Trazodone Hcl | Trazodone Hcl | 83 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 25 |
| Jardiance | Empagliflozin | 74 | 20 |
| Metformin Hcl Er | Metformin Hcl | 68 | 25 |
| Eliquis | Apixaban | 67 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 21 |
| Alendronate Sodium | Alendronate Sodium | 58 | 20 |
| Potassium Chloride | Potassium Chloride | 57 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Ozempic | Semaglutide | 55 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 15 |
| Carvedilol | Carvedilol | 53 | 12 |
| Sertraline Hcl | Sertraline Hcl | 52 | 13 |
| Allopurinol | Allopurinol | 49 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Spironolactone | Spironolactone | 48 | 13 |
| Simvastatin | Simvastatin | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 41 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Finasteride | Finasteride | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Prednisone | Prednisone | 30 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Atenolol | Atenolol | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 14 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Naproxen | Naproxen | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Meloxicam | Meloxicam | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $400.42 · 19 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, MOUNJARO, OFEV, Ozempic, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error